Pitolisant Hydrochloride
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB11642 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 31 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | insomnia (disease) | KG + DL |
| 2 | attention deficit-hyperactivity disorder | KG + DL |
| 3 | faciodigitogenital syndrome | KG + DL |
| 4 | disorder of peroxisomal alpha-, beta- and omega-oxidation | KG + DL |
| 5 | ACBD5 deficiency | KG + DL |
| 6 | Creutzfeldt-Jakob disease | KG + DL |
| 7 | narcolepsy, susceptibility to | KG + DL |
| 8 | megaconial type congenital muscular dystrophy | KG + DL |
| 9 | hypersomnia (disease) | KG + DL |
| 10 | circadian rhythm sleep disorder | KG + DL |
| 11 | chondromyxoid fibroma | KG + DL |
| 12 | narcolepsy without cataplexy | KG + DL |
| 13 | variably protease-sensitive prionopathy | KG + DL |
| 14 | attention deficit hyperactivity disorder, inattentive type | KG + DL |
| 15 | Wernicke-Korsakoff syndrome | KG + DL |
| 16 | multiple system atrophy | KG + DL |
| 17 | cerebrospinal fluid rhinorrhea | KG + DL |
| 18 | specific developmental disorder | KG + DL |
| 19 | sensory ataxia | KG + DL |
| 20 | decompression sickness | KG + DL |
| 21 | sleep disorder, initiating and maintaining sleep | KG + DL |
| 22 | spinal cord neoplasm | KG + DL |
| 23 | cranial neuralgia | KG + DL |
| 24 | borna disease | KG + DL |
| 25 | trigeminal nerve disease | KG + DL |
| 26 | low tension glaucoma | KG + DL |
| 27 | optic disk drusen | KG + DL |
| 28 | vascular myelopathy | KG + DL |
| 29 | transient retinal arterial occlusion | KG + DL |
| 30 | partial arterial retinal occlusion | KG + DL |
| 31 | occlusion of tributary of retinal vein | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.